Literature DB >> 29322484

Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations.

Martin Le Nedelec1,2, Paul Glue3, Helen Winter4, Chelsea Goulton5, Lucy Broughton6, Natalie Medlicott6.   

Abstract

Peripheral BDNF changes after ketamine administration have been proposed as a biomarker for brain BDNF changes. However, published data are conflicting and come from studies in paired animal groups. This study determined the time course of plasma BDNF concentrations following the administration of a single 10 mg/kg dose of ketamine by different routes of administration in rats. Brain BDNF concentrations in prefrontal cortex, hippocampus and cortex were measured in the same animals. Ketamine administration resulted in a rapid and robust increase in plasma BDNF concentrations that were sustained for 240 min. In contrast, there were no changes in brain BDNF concentrations in prefrontal cortex, hippocampus or cortex and there were no correlations between peripheral and central BDNF concentrations. These data suggest that peripheral BDNF is unlikely to be a useful biomarker of acute central BDNF changes following ketamine.

Entities:  

Keywords:  BDNF; Biomarker; Ketamine; Major depression; Treatment resistant

Mesh:

Substances:

Year:  2018        PMID: 29322484     DOI: 10.1007/s13346-017-0476-2

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  32 in total

1.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

2.  Release reaction of brain-derived neurotrophic factor (BDNF) through PAR1 activation and its two distinct pools in human platelets.

Authors:  Shogo Tamura; Hidenori Suzuki; Yuji Hirowatari; Masanao Hatase; Ayumi Nagasawa; Kazuhiko Matsuno; Seiichi Kobayashi; Takanori Moriyama
Journal:  Thromb Res       Date:  2011-09-14       Impact factor: 3.944

3.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

4.  Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders.

Authors:  Mia Thompson Ray; Cynthia Shannon Weickert; Eugene Wyatt; Maree J Webster
Journal:  J Psychiatry Neurosci       Date:  2011-05       Impact factor: 6.186

5.  The activation of adenosine monophosphate-activated protein kinase in rat hippocampus contributes to the rapid antidepressant effect of ketamine.

Authors:  Shi X Xu; Zhi Q Zhou; Xiao M Li; Mu H Ji; Guang F Zhang; Jian J Yang
Journal:  Behav Brain Res       Date:  2013-07-29       Impact factor: 3.332

Review 6.  BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis.

Authors:  Maryna Polyakova; Katharina Stuke; Katharina Schuemberg; Karsten Mueller; Peter Schoenknecht; Matthias L Schroeter
Journal:  J Affect Disord       Date:  2014-11-29       Impact factor: 4.839

7.  Blood BDNF concentrations reflect brain-tissue BDNF levels across species.

Authors:  Anders B Klein; Rebecca Williamson; Martin A Santini; Christoffer Clemmensen; Anders Ettrup; Maribel Rios; Gitte M Knudsen; Susana Aznar
Journal:  Int J Neuropsychopharmacol       Date:  2010-07-07       Impact factor: 5.176

8.  Essential role of brain-derived neurotrophic factor in adult hippocampal function.

Authors:  Lisa M Monteggia; Michel Barrot; Craig M Powell; Olivier Berton; Victor Galanis; Terry Gemelli; Sven Meuth; Andreas Nagy; Robert W Greene; Eric J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

9.  Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus.

Authors:  Lêda S B Garcia; Clarissa M Comim; Samira S Valvassori; Gislaine Z Réus; Luciana M Barbosa; Ana Cristina Andreazza; Laura Stertz; Gabriel R Fries; Elaine Cristina Gavioli; Flavio Kapczinski; João Quevedo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-08       Impact factor: 5.067

10.  Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?

Authors:  Janusz K Rybakowski; Agnieszka Permoda-Osip; Maria Skibinska; Rafal Adamski; Alicja Bartkowska-Sniatkowska
Journal:  Hum Psychopharmacol       Date:  2012-11-05       Impact factor: 1.672

View more
  6 in total

Review 1.  The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.

Authors:  Giordano Novak Rossi; Jaime E C Hallak; Glen Baker; Serdar M Dursun; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-13       Impact factor: 5.760

Review 2.  Towards an understanding of psychedelic-induced neuroplasticity.

Authors:  Abigail E Calder; Gregor Hasler
Journal:  Neuropsychopharmacology       Date:  2022-09-19       Impact factor: 8.294

3.  The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity.

Authors:  Melody J Y Kang; Emily Hawken; Gustavo Hector Vazquez
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

4.  Effects of subanesthetic intravenous ketamine infusion on neuroplasticity-related proteins in the prefrontal cortex, amygdala, and hippocampus of Sprague-Dawley rats.

Authors:  Michael Zhang; Kennett D Radford; Mercedes Driscoll; Salsabila Purnomo; Jean Kim; Kwang H Choi
Journal:  IBRO Rep       Date:  2019-01-16

5.  Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study.

Authors:  Paul Glue; Natalie J Medlicott; Shona Neehoff; Peter Surman; Fred Lam; Noelyn Hung; Cheung-Tak Hung
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-18

Review 6.  Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.

Authors:  Domenico De Berardis; Michele Fornaro; Alessandro Valchera; Marilde Cavuto; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Annastasia Fiengo; Antonio Ventriglio; Kim Yong-Ku; Giovanni Martinotti; Massimo Di Giannantonio; Carmine Tomasetti
Journal:  Int J Mol Sci       Date:  2018-09-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.